Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 5/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMO | Q99835 | 2/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | GPR183 | P32249 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 2/20 | 0.37 |
| ▸ | BRAF | P15056 | 2/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
| ▸ | FASN | P49327 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL939898 | 0.94 | ECE1 (0.40) | DGAT1TRPV1MAOBNPC1RAB9A | |
| SCHEMBL940147 | 0.91 | PPARG (0.46) | TRPV1RAF1BRAF | |
| SCHEMBL940314 | 0.91 | DGAT1 (0.44) | DGAT1MAOBPTGDR2NPC1RAB9A | |
| SCHEMBL2891109 | 0.89 | PPARG (0.44) | TRPV1MAOBRAF1BRAFGRIN1 | |
| SCHEMBL2895761 | 0.88 | F10 (0.43) | DGAT1TRPV1MAOBNPC1RAB9A | |
| SCHEMBL940740 | 0.87 | TRPV1 (0.39) | DGAT1TRPV1PTGDR2RAF1BRAF | |
| SCHEMBL939512 | 0.85 | TRPV1 (0.39) | DGAT1TRPV1MAOBNPC1RAB9A | |
| SCHEMBL939844 | 0.85 | PPARG (0.46) | TRPV1RAF1BRAF | |
| SCHEMBL2895000 | 0.85 | PPARG (0.44) | TRPV1RAF1BRAFGRIN1GRIN2B | |
| SCHEMBL942092 | 0.84 | KCNQ3 (0.42) | DGAT1MAOBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102143956-B | Derivatives of indole-2-carboxamides and azaindole-2-carboxamides substituted by silane groups, preparation thereof and therapeutic use thereof | SANOFI AVENTIS | 2014-04-23 | — | — | CN | claimed |
| US-8399491-B2 | Derivatives of indole-2-carboxamides and of azaindole-2-carboxamides substituted with a silanyl group, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-03-19 | — | — | US | claimed |
| EP-2235003-B1 | DERIVATIVES OF INDOLE 2-CARBOXAMIDES AND AZAINDOLE 2-CARBOXAMIDES SUBSTITUTED BY A SILANYLE GROUP, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2012-12-19 | — | — | EP | claimed |
| US-20110009365-A1 | DERIVATIVES OF INDOLE-2-CARBOXAMIDES AND OF AZAINDOLE-2-CARBOXAMIDES SUBSTITUTED WITH A SILANYL GROUP, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | claimed |
| CN-102143956-B | Derivatives of indole-2-carboxamides and azaindole-2-carboxamides substituted by silane groups, preparation thereof and therapeutic use thereof | SANOFI AVENTIS | 2014-04-23 | — | — | CN | disclosed |
| US-8399491-B2 | Derivatives of indole-2-carboxamides and of azaindole-2-carboxamides substituted with a silanyl group, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-03-19 | — | — | US | disclosed |
| EP-2235003-B1 | DERIVATIVES OF INDOLE 2-CARBOXAMIDES AND AZAINDOLE 2-CARBOXAMIDES SUBSTITUTED BY A SILANYLE GROUP, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2012-12-19 | — | — | EP | disclosed |
| US-20110009365-A1 | DERIVATIVES OF INDOLE-2-CARBOXAMIDES AND OF AZAINDOLE-2-CARBOXAMIDES SUBSTITUTED WITH A SILANYL GROUP, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009365-A1 | DERIVATIVES OF INDOLE-2-CARBOXAMIDES AND OF AZAINDOLE-2-CARBOXAMIDES SUBSTITUTED WITH A SILANYL GROUP, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | IDO2, INMT, IDO1 | DGAT1 3737/4885TRPV1 1021/4885MAOB 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.